A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2015
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Janssen-Cilag
- 25 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 according to ClinicalTrials.gov record.
- 15 Oct 2013 Planned number of patients changed from 50 to 70 as reported by ClinicalTrials.gov.